Subcutaneous Herceptin: Completed Phase III enrollment

Halozyme said Roche completed enrollment of 595 patients in the open-label, international Phase III trial to compare subcutaneous Herceptin vs. IV Herceptin given on day 1 of a 21-day cycle for 18 cyc...